Please Wait
Applying Filters...
menu
    • menu
    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-08-25

    Virtual Booth

    An Enquiry

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Avexitide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amylyx Shares Avexitide Bariatric Data at ENDO 2025
    Amylyx Shares Avexitide Bariatric Data at ENDO 2025

    13 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250713408050/en/Amylyx-Pharmaceuticals-Presents-New-Exploratory-Analyses-from-Phase-2-and-Phase-2b-Clinical-Trials-of-Avexitide-in-Post-Bariatric-Hypoglycemia-at-ENDO-2025

    BUSINESSWIRE
    13 Jul 2025
    Share Share
    Amylyx to Present Avexitide Data at ENDO 2025
    Amylyx to Present Avexitide Data at ENDO 2025

    08 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250708428715/en/Amylyx-Pharmaceuticals-to-Host-Event-to-Discuss-Post-bariatric-Hypoglycemia-and-Avexitide-at-ENDO-2025

    BUSINESSWIRE
    08 Jul 2025
    Share Share
    Amylyx Unveils Phase 3 LUCIDITY Trial For Avexitide In Hypoglycemia
    Amylyx Unveils Phase 3 LUCIDITY Trial For Avexitide In Hypoglycemia

    04 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241203046765/en

    BUSINESSWIRE
    04 Dec 2024
    Share Share
    Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
    Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

    08 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240808415481/en

    BUSINESSWIRE
    08 Aug 2024
    Share Share
    Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal
    Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal

    24 Jul 2024

    // BIOSPACE

    https://www.biospace.com/drug-development/amylyx-rebuilds-momentum-following-relyvrio-market-withdrawal

    BIOSPACE
    24 Jul 2024
    Share Share
    Amylyx Acquires Phase 3 GLP-1 Antagonist With FDA Breakthrough Status
    Amylyx Acquires Phase 3 GLP-1 Antagonist With FDA Breakthrough Status

    10 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240710172870/en

    BUSINESSWIRE
    10 Jul 2024
    Share Share